Yan Sun

10.5k citations
113 papers · 4.2k indexed · 1 hit paper · h-index 27

Impact in

  • Oncology top 1%
    • HER2/EGFR in Cancer Research
    • Lung Cancer Research Studies
    • Colorectal Cancer Treatments and Studies
    • Lung Cancer Treatments and Mutations
    • Gastric Cancer Management and Outcomes
    • Lung Cancer Diagnosis and Treatment

Papers in

    • Head and Neck Cancer Studies 18
    • Lung Cancer Research Studies 13
    • Cancer Immunotherapy and Biomarkers 9
    • Viral-associated cancers and disorders 8
    • Colorectal Cancer Treatments and Studies 8
    • HER2/EGFR in Cancer Research 7

Yan Sun

105 papers receiving 4.1k citations

Hit Papers

Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial 2008 · 1.0k citations
1.0k20082026201420202505007501000

Peers

Yan Sun
Comparison fields: 5 of 114
  • Oncology 2.3k
  • Pulmonary and Respiratory Medicine 2.1k
  • Nephrology 346
  • Cancer Research 502
  • Hematology 302
Replace Vânia Nosé with:
Vânia Nosé United States
Naoyoshi Onoda Japan
Maria E. Cabanillas United States
Kazuko Sakai Japan
Lindsey Gumbrell United Kingdom
Mark S. Talamonti United States
Mary Cabiddu Italy
Ying Huang United States
David Dodwell United Kingdom
Takamitsu Inoue Japan
Yan Sun relative to Vânia Nosé United States Vânia Nosé's profile →
Citations per field
00.5×3.2×
Vânia Nosé · 1×
Citations per year

Countries citing papers authored by Yan Sun

Since Specialization
Citations

This map shows the geographic impact of Yan Sun's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yan Sun with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yan Sun more than expected).

Fields of papers citing papers by Yan Sun

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yan Sun. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yan Sun. The network helps show where Yan Sun may publish in the future.

Co-authors

The 25 scholars most cited alongside Yan Sun, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Yan Sun Line = papers co-authored together Yan Sun links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 113 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial
Hit paper breakdown →
20081009
2 2010391
3 2010339
4 2012222
5 2008213
6 2017195
7 2010153
8 2013110
9 200898
10 200985
11 200973
12 201963
13 201655
14 200952
15 202051
16 200950
17 201250
18 201647
19 202141
20 201436

About Yan Sun

Yan Sun is a scholar working on Otorhinolaryngology, Oncology, Pulmonary and Respiratory Medicine, Nephrology and Pathology and Forensic Medicine, having authored 113 papers that have together received 4.2k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (22 papers), Head and Neck Cancer Studies (18 papers), Lung Cancer Research Studies (13 papers), Lymphoma Diagnosis and Treatment (11 papers), Cancer Immunotherapy and Biomarkers (9 papers), Viral-associated cancers and disorders (8 papers), Colorectal Cancer Treatments and Studies (8 papers) and HER2/EGFR in Cancer Research (7 papers). The work is most often cited by research in Oncology (2.3k citations), Pulmonary and Respiratory Medicine (2.1k citations), Nephrology (346 citations), Cancer Research (502 citations) and Hematology (302 citations). Yan Sun has collaborated with scholars based in China, United States and United Kingdom. Frequent co-authors include Yi‐Long Wu, Radj Gervais, Claire Watkins, Vera Hirsh, Jean‐Yves Douillard, Edward S. Kim, Martin Reck, Mark A. Socinski, Tony Mok and Scott M. Lippman. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, European Journal of Cancer, Journal of Thoracic Oncology and The Lancet Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026